GlassScriptPhysician profile
Laura Breidinger
NPI 1245513951
$6,369.19
in general payments reported to CMS, 2019-2025
35 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,273 · 2022: $1,194 · 2023: $1,442 · 2024: $1,346 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.45 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $972.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $853.99 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $681.82 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $585.05 | 2023-2025 | |
| Astellas Pharma US INC | $550.80 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $450.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $437.46 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.09 | 2021-2024 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $193.27 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $145.32 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $135.89 | 2021-2025 | Otezla, Repatha, Prolia |
| Sanofi-Aventis U.S. LLC | $126.43 | 2021 | |
| Exact Sciences Corporation | $118.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $118.58 | 2023-2024 | Nuedexta, Rexulti |
| Abbott Laboratories | $110.07 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $78.42 | 2022 | |
| Amarin Pharma, INC. | $73.53 | 2022 | |
| Merck Sharp & Dohme LLC | $48.76 | 2022-2023 | Verquvo |
| Philips North America LLC | $38.16 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $35.50 | 2021-2024 | Yupelri |
| Corcept Therapeutics | $34.79 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.78 | 2021 | |
| Ani Pharmaceuticals, INC. | $29.51 | 2025 | Purified Cortrophin Gel |
| Vertex Pharmaceuticals Incorporated | $25.81 | 2025 | |
| Novartis Pharmaceuticals Corporation | $25.45 | 2024 | |
| Sumitomo Pharma America, INC. | $25.00 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $21.89 | 2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $21.53 | 2022 | |
| Radius Health, INC. | $21.45 | 2024 | Tymlos |
| Esperion Therapeutics, INC. | $21.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.30 | 2021 | |
| Dexcom, INC. | $20.21 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $16.34 | 2025 | Flucelvax, Fluad |
| Scpharmaceuticals INC. | $15.38 | 2025 | |
| Horizon Therapeutics Plc | $14.83 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Breidinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.